Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma (aRCC) Receiving Systemic First-line (1st Line) Anti-cancer Treatment Under Daily Routine in Germany: Retrospective Medical Chart Review (RENALISTIC Study).
Reason given: The trial prematurely terminated due to the inability to recruit the planned number of participants. The decision to terminate the trial was not based on any safety and/or efficacy concerns.
Key facts
- Where
- New York, United StatesSee the site
Where in United States
- Pfizer New YorkNew York, United StatesNo longer taking part
Trial details
- Who runs it
- Pfizer
- Trial code
- NCT05534789
- Record updated
- 20 January 2025
- Original description
The purpose of this study is to learn about the treatments used in for advanced renal cell carcinoma as well as effectiveness of these treatments in the real world. Study participants must be:Read full original descriptionShow less
Clinical Outcomes and Therapy Management Among Patients With Advanced Renal Cell Carcinoma (aRCC) Receiving Systemic First-line (1L) Anti-cancer Treatment Under Daily Routine in Germany: Retrospective Chart Review (RENALISTIC Study)
The purpose of this study is to learn about the treatments used in for advanced renal cell carcinoma as well as effectiveness of these treatments in the real world. Study participants must be:
At least 18 years of age or older. Confirmed renal cell carcinoma Received first line treatment
Inclusion: Participants diagnosed with locally advanced or metastatic renal cell carcinoma; Participants with full medical information is available regarding all treatments before, during and after 1st line.